0.3mg Ranibizumab Versus 0.5mg Ranibizumab For Macular Edema Secondary To Central Retinal Vein Occlusion: A Systematic Review

Objectives:To assess the clinical effective of 0.3mg ranibizumab versus 0.5mg ranibizumab for Macular Edema secondary to Central Retinal Vein Occlusion. Methods: We searched the Cochrane Central Register of Controlled Trials (issue 3,2010), MEDLINE (1966 to Aug 2010),EMbase (1980 to Aug 2010), and CMB-disk(1979 to Aug 2010)。We also hand searched relevant journals and conference proceedings. Data were extracted by two reviewers independently using an extraction form. The Cochrane Collaboration's RevMan 5.0 software was used for statistical analysis. Results:Two RCTs involving 30 participants (30 eyes) with Macular Edema secondary to Central Retinal Vein Occlusion were included.Meta-analysis showed that compared with 0.5mg ranibizumab,0.3mg ranibizumab have no significant in increasing the best correct visual acuity(BEVA) (WMDO.92,95% CI-10.61 to 12.45),but have significant difference in reducing the macular edema(WMD 120.49,95% CI 22.71 to 218.28).Conclusion:Since the sample size of the included trials are relatively small, compared with 0.5mg ranibizumab,0.3mg ranibizumab can well reduce the macular edema but have no significant difference in increasing the BCVA, in and more well-designed large-scale RCTs are required.